<ul><li>Presenter:   </li></ul><ul><li>James A. Joyce </li></ul><ul><li>Chairman and CEO </li></ul><ul><li>This presentati...
<ul><li>Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of viru...
The Hemopurifier TM <ul><li>Hemodialysis </li></ul><ul><li>Affinity Chromatography </li></ul>An Expansive Platform Technol...
Hemopurifier TM   Advantages <ul><li>Mimics Immune Response </li></ul><ul><li>Antibody Immobilization </li></ul><ul><li>Fu...
Hemopurifier TM   Markets <ul><ul><li>Biological Weapons </li></ul></ul><ul><ul><li>HIV/AIDS </li></ul></ul><ul><ul><li>He...
Published Human Blood Studies <ul><li>55%+ removal of HIV in three hours. </li></ul><ul><li>85%+ removal of HIV in twelve ...
Biological Weapon Targets <ul><ul><li>CDC CATEGORY “A” AGENTS </li></ul></ul><ul><ul><ul><li>Smallpox Viruses </li></ul></...
Bioterrorism Challenges <ul><li>Vast Number of Targets </li></ul><ul><li>Genetic Engineering  </li></ul><ul><li>Vaccine & ...
Hemopurifier Advantages <ul><li>Adjunctive </li></ul><ul><li>Sole Solution  </li></ul><ul><li>Rapid Development & Deployme...
National Center for Biodefense <ul><li>U.S. Military - Countermeasures Against Biological Weapons </li></ul><ul><li>Improv...
<ul><li>The Aethlon Science Team </li></ul>
Richard Tullis, Ph.D. <ul><li>Developer of Infectious Disease and Biowarfare Hemopurifiers.   </li></ul><ul><li>Inventor a...
Kenneth Michael, Ph.D. <ul><li>Founder, Past President & Chairman of The Regulatory Affairs Professionals Society (RAPS), ...
Nathan W. Levin, MD <ul><li>Medical and Research Director of the Renal Research Institute, LLC. </li></ul><ul><li>Professo...
Claudio Ronco, MD <ul><li>Director of the Dialysis and Renal Transplantation at St. Bartolo Hospital in Vicenza, Italy. </...
Larry Cowgill, D.V.M., Ph.D. <ul><li>Professor in the Department of Medicine and Epidemiology at the School of Veterinary ...
Raveendran Pottathil, Ph.D. <ul><li>Former Section Director of Retroviral Research at Hoffman La Roche. </li></ul><ul><li>...
Jean-Claude Chermann, Ph.D. <ul><li>AIDS virus discoverer.  </li></ul><ul><li>Director of Research of the Pasteur Institut...
Pedro Cuatrecasas, MD <ul><li>Inventor of Affinity Chromatography. </li></ul><ul><li>Former President of Pharmaceutical Re...
Targeted 12-Month Value Drivers <ul><li>Introduction of Aethlon to the Financial Industry </li></ul><ul><li>Partnerships <...
Investment Data <ul><li>OTCBB: “AEMD” </li></ul><ul><li>Stock Price (3/26/04): $1.85 </li></ul><ul><li>Market Capitalizati...
Conclusion NOT IF, BUT WHEN
Upcoming SlideShare
Loading in …5
×

Aethlon Medical, Inc. (OTCBB: AEMD)

367 views
300 views

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
367
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
2
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Aethlon Medical, Inc. (OTCBB: AEMD)

  1. 1. <ul><li>Presenter: </li></ul><ul><li>James A. Joyce </li></ul><ul><li>Chairman and CEO </li></ul><ul><li>This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when new products are successfully developed and introduced by the Company, market acceptance of current or new products, regulatory delays, manufacturing delays, and other risks which may be detailed in Aethlon Medical’s SEC filings. </li></ul>HOMELAND DEFENSE CONFERENCE WASHINGTON, DC. MARCH 30, 2004
  2. 2. <ul><li>Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of viruses and toxins in the blood. </li></ul>“ ...at the forefront of developing promising new treatments...“ (The Washington Times)
  3. 3. The Hemopurifier TM <ul><li>Hemodialysis </li></ul><ul><li>Affinity Chromatography </li></ul>An Expansive Platform Technology Converging Established Principles
  4. 4. Hemopurifier TM Advantages <ul><li>Mimics Immune Response </li></ul><ul><li>Antibody Immobilization </li></ul><ul><li>Fusion/Entry Inhibitor </li></ul><ul><li>Multiple Disease Treatment </li></ul><ul><li>Established Infrastructure </li></ul>
  5. 5. Hemopurifier TM Markets <ul><ul><li>Biological Weapons </li></ul></ul><ul><ul><li>HIV/AIDS </li></ul></ul><ul><ul><li>Hepatitis-C (HCV) </li></ul></ul>
  6. 6. Published Human Blood Studies <ul><li>55%+ removal of HIV in three hours. </li></ul><ul><li>85%+ removal of HIV in twelve hours. </li></ul><ul><li>90% removal of gp120 in one hour. </li></ul><ul><li>58% removal of HCV in two hours. </li></ul>
  7. 7. Biological Weapon Targets <ul><ul><li>CDC CATEGORY “A” AGENTS </li></ul></ul><ul><ul><ul><li>Smallpox Viruses </li></ul></ul></ul><ul><ul><ul><li>Anthrax Bacterium </li></ul></ul></ul><ul><ul><ul><li>Botulinum Toxin </li></ul></ul></ul><ul><ul><ul><li>Hemorrhagic Fevers </li></ul></ul></ul><ul><ul><ul><ul><li>Ebola </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Marburg </li></ul></ul></ul></ul><ul><ul><li>Septic Shock Mediators </li></ul></ul><ul><ul><li>Genetically Engineered </li></ul></ul>
  8. 8. Bioterrorism Challenges <ul><li>Vast Number of Targets </li></ul><ul><li>Genetic Engineering </li></ul><ul><li>Vaccine & Drug Limitations </li></ul><ul><li>Pathogens are Inexpensive & Accessible </li></ul><ul><li>Easy to Deliver </li></ul>
  9. 9. Hemopurifier Advantages <ul><li>Adjunctive </li></ul><ul><li>Sole Solution </li></ul><ul><li>Rapid Development & Deployment </li></ul><ul><li>Addresses Military & Civilian Requirements </li></ul>
  10. 10. National Center for Biodefense <ul><li>U.S. Military - Countermeasures Against Biological Weapons </li></ul><ul><li>Improves Access to Government Grants & Contracts </li></ul><ul><li>Increases Scientific Resources, Advocates </li></ul><ul><ul><li>Charles Bailey, MD. </li></ul></ul><ul><ul><li>Ken Alibek, MD. </li></ul></ul>
  11. 11. <ul><li>The Aethlon Science Team </li></ul>
  12. 12. Richard Tullis, Ph.D. <ul><li>Developer of Infectious Disease and Biowarfare Hemopurifiers. </li></ul><ul><li>Inventor and original patent holder of Antisense, and related DNA synthesis technologies. </li></ul><ul><li>Co-founder and Director of Research of Molecular Biosystems (NYSE). </li></ul><ul><li>Founder of Synthetic Genetics, Inc., and Syngen Research, Inc. </li></ul>Aethlon Chief Scientific Officer, Director
  13. 13. Kenneth Michael, Ph.D. <ul><li>Founder, Past President & Chairman of The Regulatory Affairs Professionals Society (RAPS), an 8000 member International Regulatory Affairs Organization. </li></ul><ul><li>Director of Regulatory Affairs at Siemens Medical Systems. </li></ul>Regulatory and Clinical Affairs Advisor
  14. 14. Nathan W. Levin, MD <ul><li>Medical and Research Director of the Renal Research Institute, LLC. </li></ul><ul><li>Professor of Clinical Medicine at the Albert Einstein College of Medicine. </li></ul>SCIENCE ADVISORY BOARD / Dialysis
  15. 15. Claudio Ronco, MD <ul><li>Director of the Dialysis and Renal Transplantation at St. Bartolo Hospital in Vicenza, Italy. </li></ul><ul><li>Instrumental in the introduction of continuous hemofiltration and high flux dialysis in Europe. </li></ul><ul><li>Seventeen books on nephrology and dialysis. </li></ul><ul><li>350+ scientific papers. </li></ul><ul><li>Editorial board of twelve scientific journals. </li></ul><ul><li>Director of three international scientific societies. </li></ul>SCIENCE ADVISORY BOARD / Dialysis
  16. 16. Larry Cowgill, D.V.M., Ph.D. <ul><li>Professor in the Department of Medicine and Epidemiology at the School of Veterinary Medicine, University of California. </li></ul><ul><li>Head of companion animal dialysis at the Veterinary Medical Teaching Hospital at UC Davis and the UC Veterinary Medical Center-San Diego. </li></ul><ul><li>Leading authority in managing animal dialysis clinical programs. </li></ul>SCIENCE ADVISORY BOARD / Dialysis
  17. 17. Raveendran Pottathil, Ph.D. <ul><li>Former Section Director of Retroviral Research at Hoffman La Roche. </li></ul><ul><li>Advisor to World Health Organization’s Sexually Transmitted Diseases and Global Vaccination Program. </li></ul><ul><li>Co-founder of Specialty Biosystems, Inc. </li></ul><ul><li>President of AccuDx, Inc. </li></ul>SCIENCE ADVISORY BOARD / Infectious Disease
  18. 18. Jean-Claude Chermann, Ph.D. <ul><li>AIDS virus discoverer. </li></ul><ul><li>Director of Research of the Pasteur Institute. </li></ul><ul><li>Director of Research of INSERM ( French National Institute of Health and Medical Research ). </li></ul><ul><li>First to demonstrate that HIV is a retrovirus. </li></ul><ul><li>First use of HIV anti-retroviral agent in humans. </li></ul><ul><li>First to demonstrate HIV infection in US patients through the detection of antibodies. </li></ul>SCIENCE ADVISORY BOARD / Infectious Disease
  19. 19. Pedro Cuatrecasas, MD <ul><li>Inventor of Affinity Chromatography. </li></ul><ul><li>Former President of Pharmaceutical Research at Parke-Davis. </li></ul><ul><li>Corporate Vice President for Warner Lambert Company. </li></ul><ul><li>Senior Vice President and Director of Glaxo Inc. </li></ul><ul><li>Vice President, R&D, and Director, of Burroughs Wellcome. </li></ul><ul><li>Involved in the commercialization of over forty novel medicines. </li></ul><ul><li>Member of the National Academy of Sciences, The Institute of Medicine, American Academy of Arts & Sciences. </li></ul><ul><li>Numerous awards, including The Wolf Prize in Medicine. </li></ul><ul><li>400+ scientific publications. </li></ul>SCIENCE ADVISORY BOARD / Infectious Disease
  20. 20. Targeted 12-Month Value Drivers <ul><li>Introduction of Aethlon to the Financial Industry </li></ul><ul><li>Partnerships </li></ul><ul><li>Biowarfare Animal Data </li></ul><ul><li>Human Trial Initiation </li></ul><ul><li>Grant Income </li></ul>
  21. 21. Investment Data <ul><li>OTCBB: “AEMD” </li></ul><ul><li>Stock Price (3/26/04): $1.85 </li></ul><ul><li>Market Capitalization (3/26/04) : $16.9 million </li></ul><ul><li>Shares Outstanding (2/12/04): 9,122,711 </li></ul>
  22. 22. Conclusion NOT IF, BUT WHEN

×